Latest Alkynes Stories
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.
One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.
Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable.
BROOMFIELD, Colo., April 30 /PRNewswire/ -- Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland.
NUTLEY, N.J., April 22 /PRNewswire/ -- Roche announced today that Mike Burgess, M.D., Ph.D., has been named Head of the Oncology Discovery and Translational Area (DTA) (1), effective immediately.
SAN DIEGO, April 6 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. today announced the completion of patient enrollment to its APRiCOT-L study, a phase II clinical trial of its oral, once-daily anti-cancer agent, CapoxigemÂ® (apricoxib, TG01), in non-small cell lung cancer (NSCLC).
CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva(Â®) (erlotinib) in patients with non-small cell lung cancer (NSCLC).
Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective.
Panel Votes Against Approval of Tarceva(R) as Maintenance Drug WASHINGTON, Dec. 17 /PRNewswire-USNewswire/ -- Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.
- A woman chauffeur.
- A woman who operates an automobile.